Abstract-A panel of anomeric oxime ether derivatives of β-galactose were synthesized via the reaction of O-β-Dgalactopyranosylhydroxylamine with aldehydes. The oxime ethers were evaluated as inhibitors against galectin-3 in a competitive fluorescence polarization assay. The best inhibitor, [E]-O-(β-D-galactopyranosyl)-indole-3-carbaldoxime (E-52), had a Kd value of 182 µM, which is 24 times better than methyl β-D-galactopyranoside (Kd = 4400 µM) and in the same range as methyl lactoside (Kd = 222 µM). ©2000 Elsevier Science Ltd. All rights reserved.
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Galectin-3
1 is a member of a family of so far 14 mammalian cytosolic proteins (12 known in humans) defined in 1994 2 as follows: "Membership in the galectin family requires fulfilment of two criteria: affinity for βgalactosides and significant sequence similarity in the carbohydrate-binding site…". Galectin-3 is an intra-and extra-cellular lectin with a correlation of expression and functional implication in inflammation [3] [4] and the aggressiveness and metastatic potential of cancer 5 . Galectin-3 appears to mediate most of its functions via interaction of its carbohydrate recognition domain (CRD) with glycoproteins (extracellular and at cell surface), and also non-glycosylated molecules (intracellular). The CRD of galectin-3 is a 130 aa beta-sandwich with a groove on one side that fits about a tetrasaccharide and can be described as four subsites-A, B, C and D 1 . Subsite C is built from most of the conserved amino acids characteristic for galectins and binds galactose with many interactions. In natural saccharides, the galactose residue glycosylates another pyranoside that in turn occupies subsite D. The residue in subsite D is typically (1→ 4)-linked Glc or GlcNAc or (1→3)-linked GlcNAc or GalNAc . Natural saccharides have been proposed as inhibitors of galectins. However, they are difficult to synthesize, sensitive to hydrolysis and they are typically to polar to be used as drugs. One approach to circumvent these disadvantages of glycosides is to prepare inhibitors of galectins in which the saccharide in site D is replaced by simpler and less polar structures. This is reasonable as site D interacts only with a small part of the bound saccharide and therefore might accommodate other structures. Within this context, we herein report the synthesis of anomeric aldoxime derivatives of β-galactose via the reaction of O-β-D-galactopyranosyl hydroxylamine 6 (1 ) with aldehydes. Non-anomeric carbohydrate aldoxime ethers were recently reported as inhibitors of mucin-type O-glycosylation 7 . The anomeric oxime ethers are expected to possess improved stability against enzymatic hydrolysis and are relatively stable at physiological pH. In addition, more hydrophobic aldoximes may have improved cell membrane permeability. Hence, a panel of 51 oxime ethers 2-52 were prepared in good to excellent yields by reacting 1 6,8 with different aldehydes of varying size, polarity and geometry 9 (Scheme 1). The lower yields obtained for some of the aldoximes are mainly due to lower purities of starting aldehydes, which resulted in uncharacterized by-products and in some cases incomplete reactions. Dissociation constants for oxime ethers 2-52 (Scheme 1) with galectin-3 were determined by competitive fluorescence polarization 10 and compared to the known reference compounds D-galactose (Kd=4400 µM), lactose (Kd=222 µM) and N-acetyllactosamine (Kd=67 µM 11 ) as methyl β -glycosides. The first important overall observation was that the structure of the aldehyde component greatly influenced the affinity of the inhibitors for galectin-3, as several inhibitors were superior to methyl β-D-galactoside and some were equal or even worse. The aminoxy compound 1 (Kd= 4199 µM) and oxime ether 2 (Kd= 8860 µM) had no improved binding as compared to the methyl galactoside. It can thus be concluded that the aminoxy moiety has no or only a minor influence on the Kd values. Aliphatic moieties (2, 10, 18, 25, 31, 32, 43, 46, 50) had no effect or resulted in even weaker binding as compared to 1. Furthermore, only a minor improvement of binding, as compared to 1, was seen with an unsubstituted phenyl 47 (Kd= 3473 µM). However, a hydroxyl group at ortho (3, Kd= 1193 µM) or meta (11, Kd= 1835 µM) position of phenyl oximes appeared important, while a hydroxyl at para position (19) resulted in slightly weaker binding. Dihydroxylation (26, 33, and 3 9 ) further improved the affinity for galectin-3, although the relatively strong inhibition by the 2 ,4-and and 33 is difficult to rationalize as they carry one hydroxy group para to the aldoxime group. However, as natural ligands position a sugar moiety to form hydrogen bonds in subsite D, it is reasonable to assume that the affinityenhancing effects of the hydroxylated aldoximes (3, 11, 26, 33 , and 39) are due to hydrogen bonding to subsite D. A nitro group in meta position ( (7, 14, 15, 18, 22, 23, 25, 32, 36, 44, 46, 52) were obtained as mixtures (E/Z 10/1 to 3/1). Assignment of E/Zconfigurations were based on chemical shifts of oxime protons [12] [13] [14] . A successful attempt to separate the isomers of the indole-3-carbaldoxime 52 (E/Z 3/1) was made using C-18 RP-HPLC and pure [E]-and [Z]-indole-3-carbaldoxime were isolated. Unfortunately, attempts to separate the E/Zisomers of 14, 44 and 45 were unsuccessful. The E-and Zisomers of 52 displayed different Kd values with the Eisomer (Kd=182 µM) being better than the Z-isomer (Kd=549 µM), which suggests that a close contact between the indole ring and galectin-3 binding site confers selectivity towards the E-isomer. In order to exclude the possibility of E/Z-isomerization during biological evaluations, compound E-52 was dissolved in deuterated bioassay buffer (PBS, pH 7.2) and analysed with 1 H NMR for 6 days. No E/Z-isomerization could be observed and as inhibitors were dissolved in buffer and evaluated as galectin-3 inhibitors within the same day, we conclude that E/Z-isomerizations do not interfere with evaluation of the pure isomers of 52.
In conclusion, through a panel of structurally simple galactosyl oxime ethers, the glucose moiety of lactose has been replaced by less complex organic structures that provide improved affinity (Kd= 182 µM for E-52) for galectin-3 as compared to methyl lactoside (Kd= 222 µM). Furthermore, the indole derivative E-52 show 24 times affinity enhancement for galectin-3 as compared to methyl β-D-galactoside. The use of oxime ethers results in less hydrogen bonding and less polar molecules, possibly with improved stability against enzymatic hydrolysis, and thus constitutes an advancement towards novel galectin inhibitors with improved pharmacological properties as compared to natural ligands. Finally, combination of the present strategy with the previously published targeting of subsite B 11, 15 might give much stronger binding inhibitors with improved pharmacological properties.
